© 2025 HSP News Service, L.L.C.
In a study reported in the Journal of the National Cancer Institute, Unger et al found that use of finasteride vs placebo in the Prostate Cancer Prevention Trial was associated with a modestly increased risk of depression and a modestly reduced risk of procedures for benign prostatic...
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
The ProtecT study findings1 are provocative. Despite having a control arm of active monitoring with serial prostate-specific antigen (PSA) testing, as compared with watchful waiting in the prior randomized trials (ie, SPCG-42 and PIVOT3), and also enrolling men with more favorable-risk disease...
In the UK ProtecT trial reported in The New England Journal of Medicine, Freddie C. Hamdy, FRCS, FMedSci, of the University of Oxford, and colleagues found no significant differences in prostate cancer–specific or overall mortality among men with clinically localized prostate cancer detected by...
In an analysis of the Cancer Prevention Study II (CPS-II) study cohort reported in the Journal of Clinical Oncology, Jacobs et al found no significant association between vasectomy and overall prostate cancer incidence or mortality. A recent prospective study had shown an association of vasectomy...
For men with intermediate-risk prostate cancer, side effects at 2 years following radiation therapy were comparable for extremely hypofractionated treatment, which was delivered in 7 fractions across 2.5 weeks, and conventional treatment of 39 fractions across 8 weeks, according to research...
High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
Patient-reported outcomes differed among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who were randomized to receive active monitoring, surgery, or radiotherapy in the UK ProtecT trial, according to a report by Donovan et al in The New England Journal of...
For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy offers comparable health-related quality of life outcomes in one-third less treatment time than conventional radiation therapy, according to research presented by Watkins Bruner et al at the 58th...
Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer. (Plenary Lecture 1, Presentation 7)
Alan Pollack, MD, PhD, of the University of Miami Health System, summarizes a session that included discussion of outcomes, dose response, oligometastatic disease, and gene predictor of response. (Presentations 228-235)
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...
In a new study, men who underwent vasectomy did not have an increased risk of prostate cancer, nor were they more likely to die from prostate cancer than men who did not receive this procedure. According to the researchers, this is the largest prospective study of vasectomy and fatal prostate...
A collaborative Cleveland Clinic–Mayo Clinic team of researchers has shown for the first time that patients with advanced prostate cancer are more likely to die earlier of their disease if they carry a specific testosterone-related genetic abnormality. The findings, published by Hearn et al in The...
The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid) or docetaxel/prednisone, in the phase III Mainsail trial. de Morrée et al reported this ...
A drop in the number of cancer cells detected in a patient’s blood could be the best indicator yet as to whether treatment for prostate cancer is working. A new study, published by Lorente et al in European Urology, shows that a 30% decline in a patient’s numbers of circulating tumor...
In a UK trial (ProtecT) reported in The New England Journal of Medicine, Hamdy et al found no significant differences in prostate cancer–specific or overall mortality among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who underwent active monitoring,...
In an analysis of a clinical trial population reported in the Journal of Clinical Oncology, Giacalone et al found that prostate-specific antigen (PSA) failure was associated with an increased risk of mortality among men with unfavorable-risk prostate cancer who had no or minimal comorbidity burden. ...
Sumanta K. Pal, MD, has had a longer career in oncology than many other colleagues his age. Perhaps the reason for that may center on his starting college at the age 13 and medical school at the age of 17. Today this internationally recognized leader in genitourinary cancers is Assistant Professor ...
The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid; DPL) or docetaxel/prednisone (DP), in the phase III Mainsail trial. de Morrée et...
For at least the past quarter of a century, radiobiologists and radiation oncologists have debated the role of hypofractionation (fewer total fractions with a higher dose per fraction) for prostate cancer. The debate stems from the unique radiobiology of prostate cancer and the best means to...
Jemal et al described findings indicating a continued decline in the incidence of localized/regional-stage prostate cancer at 2 years after the U.S. Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) screening in men aged ≥ 50 years in 2011, in a letter ...
Two recent European phase III trials with different study designs focused on hypofractionated vs conventional radiotherapy in localized prostate cancer. Investigators in the CHHiP trial1 showed that the hypofractionated approach is noninferior to standard fractionation, with no increase in side...
In a retrospective multicohort study reported in The Lancet Oncology, Hearn et al found that the inherited HSD3B1 (1245C) allele was significantly associated with resistance to androgen-deprivation therapy and poorer outcome in men with prostate cancer. HSD3B1 (1245A>C) has been linked to...
Approximately one in four patients who undergo radical prostatectomy experience a cancer recurrence. Now a study by Stura et al investigating a prostate-specific antigen (PSA)-based computational model that uses four consecutive postsurgical PSA values has found the mathematical model to be highly...
A novel magnetic resonance imaging (MRI) method that detects low levels of zinc ion can help distinguish healthy prostate tissue from cancer, The University of Texas (UT) Southwestern Medical Center radiologists have determined. The findings were published by Clavijo Jordan et al in the Proceedings ...
Radiation for prostate cancer typically requires 40 to 45 daily treatments, given over 8 to 9 weeks. Long fractionation schemes are chosen for most cancers, because they allow for tumor killing while reducing the potential for injury to normal tissue. However, the radiobiology of prostate cancer...
In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional radiotherapy in disease-free survival...
In an international, single-arm phase IIIB trial reported in The Lancet Oncology, Saad et al found benefit with the addition of abiraterone (Zytiga) or enzalutamide (Xtandi) to radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer. This early-access program was...
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar domain-specific quality-of-life or pathologic outcomes at 12 weeks in men with newly diagnosed, clinically localized prostate cancer, according to the results of a randomized phase III trial reported ...
Men with very high-risk prostate cancer treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy) have half of the mortality risk of men who are treated at hospitals with the lowest proportions, according to a new study conducted by...
In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported by Lee et al in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional hypofractionated...
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital (BWH) found that race significantly affected longevity by increasing the likelihood of death after receiving androgen-deprivation therapy. These findings were published by Kovtun et al in...
There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or conventional radiotherapy (given over 8–9 weeks). A new study presented at the 2016 ASCO Annual Meeting...
Although active surveillance for patients with low-risk prostate cancer has become an increasingly acceptable strategy for disease management, many men opt for definitive therapies such as radical prostatectomy or radiation therapy. A new study of more than 2,200 patients with low-risk prostate...
Active surveillance has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low-risk prostate cancer. However, what is the impact of active surveillance on health-related quality of life in patients selected or opting for this...
Smith et al found no improvement in overall survival with cabozantinib (Cometriq) vs prednisone in patients with previously treated metastatic castration-resistant prostate cancer, in the phase III COMET-1 trial reported in the Journal of Clinical Oncology. Cabozantinib, which inhibits MET, VEGF...
Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the Oregon Health & Science University (OSHU) Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate...
A University of Michigan study published by Piert et al in The Journal of Nuclear Medicine reported that the addition of molecular imaging based on F-18-choline positron-emission tomography (PET) improves the identification of significant prostate cancer over multiparametric prostate magnetic...
The incidence of mutations in DNA-repair genes was significantly higher among men with metastatic prostate cancer than among men with localized disease (11.8% vs 4.6%), according to a study by Pritchard et al reported in The New England Journal of Medicine. In addition, the frequency ...
Investigators of two European phase III trials have reached different conclusions on whether hypofractionated radiotherapy should replace conventional radiotherapy as a new standard of treatment in localized prostate cancer. The CHHiP trial findings favoring hypofractionation were reported by David ...
With surgical removal at the front line of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society...
The addition of prostate external-beam radiation therapy to androgen-deprivation therapy was associated with prolonged overall survival in men with newly diagnosed metastatic prostate cancer, according to a National Cancer Database analysis reported by Rusthoven et al in the Journal of Clinical...